Opportunity Information: Apply for PAR 23 304
This NIH grant opportunity (PAR-23-304) is an R01 funding mechanism that supports clinical trial-required research focused on reducing health and healthcare disparities tied to non-communicable and chronic diseases (NCDs) that drive the highest burden and mortality in Latin America and in U.S. Hispanic/Latino populations. The core aim is to fund intervention research that can measurably improve health outcomes by testing approaches in real clinical, health system, and community settings. The emphasis is on innovative, interdisciplinary projects that do more than describe disparities; applicants are expected to design and evaluate solutions that address them.
A central feature of the NOFO is the expectation of genuine multinational and multidisciplinary collaboration. Research teams must meaningfully partner with key stakeholders, and the application must include at least one Principal Investigator (PI) or Multiple Principal Investigator (MPI) based at an institution in Latin America. That requirement signals that projects should be grounded in local context, capacity, and priorities, rather than being led solely from the United States with limited regional engagement. In practice, that typically means shared leadership, clear roles for Latin American investigators, and study plans that reflect local healthcare delivery realities, cultural factors, and implementation constraints.
The interventions supported under this opportunity can span clinical interventions (for example, patient-level or provider-level strategies delivered in healthcare settings), health services interventions (such as care delivery redesign, quality improvement models, or system-level changes that affect access, continuity, or quality of care), and community-based interventions (including public health and community-partnered strategies that influence prevention, detection, adherence, self-management, or risk factor reduction). While the specific diseases are not listed in the provided excerpt, the framing is explicitly about NCDs and chronic diseases with the greatest burden and mortality, which generally includes areas like cardiovascular disease, diabetes, chronic respiratory conditions, cancer, and related chronic comorbidities that disproportionately affect vulnerable groups. The disparity focus also implies attention to structural, social, geographic, and healthcare-access drivers that lead to unequal outcomes.
Because this is labeled “Clinical Trial Required,” applicants should plan for a study design that meets NIH’s definition of a clinical trial, meaning the project prospectively assigns human participants (or groups) to an intervention to evaluate effects on health-related biomedical or behavioral outcomes. That requirement matters for everything from study design and outcomes selection to participant protections, trial registration, data and safety monitoring, and the overall rigor expected for an R01-level trial. In other words, this opportunity is geared toward testing interventions with clear evaluation plans rather than purely observational or descriptive research.
Eligibility is broad across U.S.-based organizational types, reflecting NIH’s intent to reach universities, health systems, governments, nonprofits, and other entities that can run complex intervention studies. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other entities. The NOFO also highlights interest in a range of mission-driven institutions and organizations that often serve historically underserved populations or have deep community reach, such as Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based and community-based organizations, regional organizations, and U.S. territories or possessions.
At the same time, there are specific restrictions related to foreign eligibility that applicants need to read carefully. Non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, “foreign components,” as defined in the NIH Grants Policy Statement, are allowed. Practically, this means the applicant organization must be eligible under NIH rules (typically U.S.-based), but the research can include work performed abroad through an approved foreign component, consistent with NIH policy. This structure fits the collaborative intent: a U.S.-eligible applicant can submit the grant while integrating substantive Latin America-based leadership and research activities through allowable foreign components and through the required inclusion of a Latin America-based PI or MPI.
Administrative details in the source indicate the sponsoring agency is the National Institutes of Health, the funding instrument is a grant, and the opportunity is categorized under education and health with CFDA numbers 93.307, 93.313, and 93.361. The opportunity was created on October 12, 2023, and the original closing date listed is January 6, 2027. The excerpt does not provide an award ceiling or expected number of awards, so applicants would need to consult the full NOFO for budget expectations, project period limits, institute/center participation, review criteria, and any specific requirements about study populations, outcomes, dissemination, or implementation planning.
Overall, the opportunity is designed for teams that can run rigorous intervention trials and also navigate the on-the-ground realities of healthcare inequities across Latin America and within U.S. Hispanic/Latino communities. Successful applications are likely to be those that pair strong clinical trial methods with credible, shared leadership across borders, meaningful community and health system partnerships, and interventions that are feasible, scalable, and directly aimed at reducing inequities in chronic disease outcomes.Apply for PAR 23 304
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307, 93.313, 93.361.
- This funding opportunity was created on 2023-10-12.
- Applicants must submit their applications by 2027-01-06.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH PAR-23-304 (R01) - Clinical Trial Required - Reducing NCD-Related Health Disparities in Latin America and U.S. Hispanic/Latino Populations
What is PAR-23-304?
PAR-23-304 is a National Institutes of Health (NIH) grant opportunity that uses the R01 research project grant mechanism to support clinical trial-required intervention research aimed at reducing health and healthcare disparities linked to non-communicable and chronic diseases (NCDs). The focus is on conditions driving the highest burden and mortality in Latin America and in U.S. Hispanic/Latino populations.
What is the main goal of this funding opportunity?
The central goal is to fund intervention studies that can measurably improve health outcomes by testing approaches in real-world clinical, health system, and community settings. The emphasis is on projects that go beyond describing disparities and instead design and evaluate solutions that address them.
What type of NIH funding mechanism is this?
This opportunity uses the R01 mechanism, which is intended to support substantial, rigorous research projects. In this case, it specifically supports intervention research that qualifies as a clinical trial under NIH definitions.
Is a clinical trial required for this opportunity?
Yes. This Notice of Funding Opportunity (NOFO) is labeled "Clinical Trial Required," meaning the proposed research must meet NIH's definition of a clinical trial.
What does "Clinical Trial Required" mean in practice?
It means the project must prospectively assign human participants (or groups) to an intervention in order to evaluate effects on health-related biomedical or behavioral outcomes. This affects how applicants should plan the study design, outcome measures, participant protections, trial-related oversight, and the overall rigor expected for an R01-level trial.
What kinds of research are most strongly aligned with this NOFO?
The NOFO is geared toward intervention research designed to reduce disparities, tested in real settings such as clinics, health systems, or communities. Projects are expected to include clear evaluation plans and measurable outcomes, rather than being purely observational, descriptive, or disparity-documentation studies.
What populations are emphasized?
The opportunity targets health and healthcare disparities affecting populations in Latin America and U.S. Hispanic/Latino communities, particularly disparities tied to non-communicable and chronic diseases associated with high burden and mortality.
What disease areas does the opportunity cover?
The excerpt does not list specific diseases, but it frames the scope as non-communicable and chronic diseases with the greatest burden and mortality. This generally includes conditions such as cardiovascular disease, diabetes, chronic respiratory conditions, cancer, and related chronic comorbidities, particularly where vulnerable groups experience disproportionate impacts.
What types of interventions are allowed or encouraged?
The opportunity supports a range of intervention types, including:
- Clinical interventions (patient-level or provider-level strategies delivered in healthcare settings)
- Health services interventions (care delivery redesign, quality improvement models, or system-level changes affecting access, continuity, or quality of care)
- Community-based interventions (public health and community-partnered strategies influencing prevention, detection, adherence, self-management, or risk factor reduction)
Does the NOFO require multinational collaboration?
Yes. A central feature is the expectation of genuine multinational and multidisciplinary collaboration, including meaningful partnerships with key stakeholders.
Is a Latin America-based Principal Investigator required?
Yes. The application must include at least one Principal Investigator (PI) or Multiple Principal Investigator (MPI) who is based at an institution in Latin America.
What does the Latin America-based PI/MPI requirement signal about project leadership?
It signals that projects should be grounded in local context, capacity, and priorities, rather than being led solely from the U.S. with limited regional engagement. In practical terms, this implies shared leadership, clear roles for Latin American investigators, and study plans reflecting local healthcare delivery realities, cultural factors, and implementation constraints.
Do projects need to partner with stakeholders?
Yes. The opportunity emphasizes meaningful partnerships with key stakeholders, consistent with conducting interventions in real clinical, health system, and community settings.
Who is eligible to apply as the applicant organization?
Eligibility is broad across U.S.-based organizational types. Eligible applicants include many government entities, higher education institutions, tribal organizations, nonprofits (with or without 501(c)(3) status), and for-profit organizations (including small businesses), among other eligible entities listed in the excerpt.
What types of U.S. organizations are listed as eligible?
The excerpt lists eligibility for:
- State, county, city/township, and special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized tribal governments and other tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits with and without 501(c)(3) status
- For-profit organizations (other than small businesses) and small businesses
- Other entities
Does the NOFO express interest in specific institution types that serve underserved communities?
Yes. The excerpt highlights interest in applications from or involving mission-driven institutions and organizations that often serve historically underserved populations or have strong community reach, such as Hispanic-serving institutions, HBCUs, TCCUs, Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, faith-based and community-based organizations, regional organizations, and U.S. territories or possessions.
Can a non-U.S. (foreign) institution apply as the primary applicant?
No. The excerpt states that non-domestic (non-U.S.) entities and foreign institutions are not eligible to apply as the applicant organization. Non-domestic components of U.S. organizations are also not eligible to apply.
If foreign institutions cannot apply, how can work in Latin America be included?
The excerpt indicates that "foreign components," as defined in the NIH Grants Policy Statement, are allowed. Practically, this means a U.S.-eligible applicant organization can submit the application while including substantive research activities performed abroad through an approved foreign component, consistent with NIH policy.
How does the NOFO balance U.S. applicant eligibility with required Latin America leadership?
The structure described in the excerpt supports collaboration by requiring at least one Latin America-based PI/MPI while still restricting the applicant organization to eligible (typically U.S.-based) applicants. Latin America-based work can be incorporated via allowable foreign components and through shared leadership arrangements.
What is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
What is the funding instrument?
The funding instrument is a grant.
What subject areas is this opportunity categorized under?
The opportunity is categorized under education and health.
What CFDA numbers are associated with this opportunity?
The excerpt lists CFDA numbers 93.307, 93.313, and 93.361.
When was this opportunity created?
The excerpt states the opportunity was created on October 12, 2023.
What is the listed closing date?
The original closing date listed in the excerpt is January 6, 2027.
Does the excerpt include an award ceiling or expected number of awards?
No. The excerpt does not provide an award ceiling or the expected number of awards.
What key details are not included in the excerpt that applicants would typically confirm in the full NOFO?
Based on the excerpt, applicants would need to consult the full NOFO for items such as budget expectations, project period limits, institute/center participation, review criteria, and any specific requirements regarding study populations, outcomes, dissemination, or implementation planning.
What kinds of projects are likely to be most competitive, based on the excerpt?
Projects that combine strong clinical trial methods with credible, shared cross-border leadership, multidisciplinary expertise, meaningful community and health system partnerships, and interventions that are feasible, scalable, and directly aimed at reducing inequities in chronic disease outcomes are described as a strong fit for the opportunity.
Browse more opportunities from the same category: Education, Health
Next opportunity: F24AS00175- Rapid Response Fund for Aquatic Invasive Species
Previous opportunity: FY2023 Historic Preservation Fund- Save America's Treasures Preservation Grants
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 304
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 304) also looked into and applied for these:
| Funding Opportunity |
|---|
| Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Apply for PAR 23 303 Funding Number: PAR 23 303 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) Apply for RFA CA 24 006 Funding Number: RFA CA 24 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Applying Imaging Pipelines for Spatial Characterization of Cellular Interactions in HIV-related CNS Pathology and/or Substance Use (R61/R33 Clinical Trial Not Allowed) Apply for RFA DA 24 030 Funding Number: RFA DA 24 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 012 Funding Number: RFA DA 25 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 013 Funding Number: RFA DA 25 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Tools for decentralized clinical trials for substance use disorder (R43/R44 Clinical Trials Optional) Apply for RFA DA 25 052 Funding Number: RFA DA 25 052 Agency: National Institutes of Health Category: Education, Health Funding Amount: $295,924 |
| Tools for Decentralized Clinical Trials for Substance Use Disorder (R41/R42 Clinical Trials Optional) Apply for RFA DA 25 051 Funding Number: RFA DA 25 051 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,972,828 |
| Resource Center for Cannabis and Cannabinoid Research (U24 Clinical Trial Not Allowed) Apply for RFA AT 24 006 Funding Number: RFA AT 24 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $850,000 |
| Effect of HIV and Substance Use Comorbidity on the Placenta and Maternal Outcomes (R01 Clinical Trial Optional) Apply for RFA DA 25 021 Funding Number: RFA DA 25 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Short Courses in Social Determinants of Health for Research Education in Nursing Research (R25 Independent Clinical Trial Not Allowed) Apply for RFA NR 24 002 Funding Number: RFA NR 24 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Advancing Technologies to Improve Delivery of Pharmacological, Gene Editing, and other Cargoes for HIV and SUD Mechanistic or Therapeutic Research (R01 Clinical Trial Optional) Apply for RFA DA 25 022 Funding Number: RFA DA 25 022 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) Apply for PAR 24 039 Funding Number: PAR 24 039 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3 Clinical Trials Optional) Apply for RFA DA 25 058 Funding Number: RFA DA 25 058 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) Apply for PAR 23 314 Funding Number: PAR 23 314 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) Apply for PAR 23 313 Funding Number: PAR 23 313 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Single Source: AIDS and Cancer Specimen Resource (ACSR; UM1 Clinical Trials Not Allowed) Apply for RFA CA 23 043 Funding Number: RFA CA 23 043 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Genomic Medicine Research (R01 Clinical Trial Optional) Apply for RFA HG 23 032 Funding Number: RFA HG 23 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required) Apply for PAR 24 053 Funding Number: PAR 24 053 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advancing Genomic Medicine Research (R21 Clinical Trial Optional) Apply for RFA HG 23 033 Funding Number: RFA HG 23 033 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Rural Community-Centered Drug Misuse Prevention and Harm Reduction Research: Addressing Implementation, Dissemination, and Equity Challenges across the Continuum of Care (R61/R33 Clinical Trial Only) Apply for RFA DA 24 036 Funding Number: RFA DA 24 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 304", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.